04.0.11aget 28 EFTA00506097 EPB-510 is a highly differentiated approach to HCV Nucleotide Polymerase Inhibitors (NPIs) • Recent data from 2012 AASID confirm the critical role NPIs will play as the cornerstone of future DAA therapies for HCV • HCV nucleotide polymerase inhibitors have clustered